Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Investigation of the M2a- Taper™ Hip System

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients having primary cemented or cementless total hip replacement for non-inflammatory degenerative joint disease (NIDJD), or any of its composite diagnoses of:~  1. Osteoarthritis,~ 2. Avascular Necrosis,~ 3. Traumatic arthritis,~ 4. Subcapital fracture,~ 5. Legg Perthes,~ 6. Slipped Capital Epiphysis,~ 7. Fracture of the pelvis,~ 8. Diastrophic Variant~* Patients with full skeletal maturity.~* Patients undergoing unilateral total hip arthroplasty or bilateral total hip arthroplasty, either staged or simultaneously.~* Patients of all races and gender.~* Patients who are able to follow postoperative care instructions.~* Patients who are able and willing to return for follow-up evaluations.~* Patients have a preoperative total Harris Hip Score less than 70 with at least moderate pain.~Exclusion Criteria~* Patients diagnosed with inflammatory degenerative arthritis (IDJD) to include the following composite diagnoses: rheumatoid arthritis, systemic lupus erythematous, pigmented villonodular synovitis, juvenile rheumatoid arthritis and other arthritic processes of inflammatory or autoimmune etiology.~* Patients less than 18 years.~* Patients with the presence of a previous prosthetic hip replacement device (any type, including surface replacement arthroplasty, endoprosthesis, etc.) in the hip joint to be operated.~* Patients with previous Girdlestone procedures.~* Patients with above the knee amputation of the contralateral and/or ipsilateral leg.~* Patients with osteoporosis, or marked bone loss which would preclude proper fixation of the prosthesis.~* Patients who are pregnant.~* Patients with an active or suspected infection in or around the hip.~* Patients with Parkinson's disease.~* Patients with vascular insufficiency, muscular atrophy, or neuromuscular disease in the affected limb.~* Patients with severe instability or deformity of the ligaments and/or surrounding soft tissue which would prelude stability of the prosthesis.~* Patients with a highly communicable disease or diseases that may limit follow-up (e.g. immuno-compromised conditions, hepatitis, active tuberculosis, neoplastic disease, etc.).~* Patients unwilling or unable to comply with a rehabilitation program for a cemented or cementless total hip replacement or who indicate difficulty or inability to return for follow-up visits prescribed by the study protocol.~* Patients with previous hip surgery or conditions that may interfere with the total hip replacement's survival or outcome, e.g., Paget's disease, Charcot's disease, severe osteoporosis compromising bone stock (Dorr type C bone).~* Patients who qualify for inclusion in the study, but refuse consent to participate in the study.~* Patients with a fused hip.~* Patients who have had a total hip arthroplasty on the contralateral hip within the last year.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- M2a- Taper™ Hip System (Type: None): M2a- Taper™ Hip System

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy